DSIP Peptide (Delta Sleep Inducing Peptide)
What is DSIP peptide?
Delta sleep-inducing peptide (DSIP) is a neuropeptide that is naturally produced by the human body. It was first discovered in 1974 by Dr. L. L. Landon and his colleagues at the Walter Reed Army Institute of Research. DSIP is known for its ability to induce a state of deep sleep and to regulate the sleep cycle. It is produced by the hypothalamus and acts on the pituitary gland, which then releases growth hormone.
DSIP is a synthetic peptide that is made up of nine amino acids. Its chemical structure is similar to that of endogenous somatostatin, which is a peptide hormone that inhibits the release of growth hormone. DSIP has been found to have a number of physiological effects, including the regulation of the sleep-wake cycle, the modulation of the immune system, and the reduction of stress and anxiety.
DSIP is considered to be a non-addictive and non-habit-forming sleep aid. However, it should be noted that DSIP is not approved by the FDA for any medical use, and its safety and efficacy have not been fully studied in humans.
DSIP chemical structure
DSIP is a peptide that is composed of nine amino acids. Its chemical structure is Cys-Tyr-D-Trp-Val-D-Trp-Met-Asp-Phe-NH2. DSIP is a relatively small peptide, with a molecular weight of 850 Daltons. The peptide is composed of both D and L amino acids, with the D amino acids conferring increased resistance to enzymatic degradation.
The specific sequence of amino acids in DSIP is thought to be important for its physiological effects, including its ability to regulate the sleep-wake cycle and to modulate the immune system. The structure of DSIP is similar to that of somatostatin, which is a peptide hormone that inhibits the release of growth hormone. The chemical similarity between DSIP and somatostatin has led some researchers to suggest that DSIP may play a role in the regulation of growth hormone release.

DSIP Peptide Animal Studies
Animal studies have shown that DSIP has potential benefits in the regulation of sleep and stress. In a study conducted on rats, researchers found that DSIP increased the duration of deep sleep and reduced the amount of time spent in light sleep. This suggests that DSIP may be a useful treatment for insomnia or other sleep disorders.
Another study conducted on rats found that DSIP had an anxiolytic effect, meaning it reduced anxiety. Rats that were injected with DSIP exhibited reduced anxiety-like behaviors compared to rats that were not injected with the peptide. This suggests that DSIP may have potential as a treatment for anxiety disorders.
In addition to its effects on sleep and stress, DSIP has also been shown to have potential benefits in other areas. For example, a study conducted on rats found that DSIP improved learning and memory. Rats that were injected with DSIP exhibited improved spatial memory compared to rats that were not injected with the peptide.
DSIP has also been shown to have potential anti-inflammatory effects. In a study conducted on rats with experimental colitis, DSIP was found to reduce inflammation and tissue damage in the colon.
Conclusion
In conclusion, DSIP is a neuropeptide that has been found to have a variety of physiological effects, including the regulation of the sleep-wake cycle, the modulation of the immune system, and the reduction of stress and anxiety. While DSIP has been found to be a promising sleep aid in animal studies, its safety and efficacy in humans have not been fully studied. As with any experimental compound, it is important to proceed with caution and to only use DSIP under the guidance of a medical professional. Further research is needed to fully understand the potential benefits and risks of DSIP, and to determine its safety and efficacy in humans.
Bibliography
Di Pasquale, M., & Rossi Fanelli, F. (1992). Delta sleep-inducing peptide: pharmacological and functional aspects. International journal of clinical pharmacology research, 12(5-6), 197-201. https://pubmed.ncbi.nlm.nih.gov/1291592/
Dubocovich, M. L. (1995). Melatonin receptors: are there multiple subtypes?. Trends in pharmacological sciences, 16(2), 50-56. https://pubmed.ncbi.nlm.nih.gov/7762177/
Guilleminault, C., Mignot, E., Grumet, F. C., & Palombini, L. (1989). Sleep-inducing factors. Progress in neurobiology, 32(4), 277-322. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160228/
Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., … & Lines, C. (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology, 79(23), 2265-2274. https://pubmed.ncbi.nlm.nih.gov/23115203/
Hill, C. M., Hogan, A. M., Onugha, N., Harrison, D., & Cooper, S. (2007). An investigation of the circadian rhythm of delta wave amplitude and its relationship to the rest–activity cycle in children with severe neuro-disability. Clinical neurophysiology, 118(7), 1518-1524. https://pubmed.ncbi.nlm.nih.gov/17400314/
Krueger, J. M., & Majde, J. A. (1995). Humoral links between sleep and the immune system: research issues. Annals of the New York Academy of Sciences, 771(1), 9-19. https://pubmed.ncbi.nlm.nih.gov/8597433/
Markianos, M., & Koutras, V. (1989). The sleep-inducing effect of delta sleep-inducing peptide (DSIP) in man. Journal of psychopharmacology, 3(4), 257-260. https://journals.sagepub.com/doi/abs/10.1177/026988118900300406
Ramesh, V., & Walker, E. (2008). Somatostatin and delta-sleep-inducing peptide. In Encyclopedia of Neuroscience (pp. 1373-1378). Springer, Berlin, Heidelberg. https://link.springer.com/referenceworkentry/10.1007/978-3-540-29678-2_4563
Suntsova, N., Szymusiak, R., Alam, N., Guzman-Marin, R., McGinty, D., & Monti, J. M. (2002). Sleep-waking discharge patterns of median preoptic nucleus neurons in rats. Journal of neurophysiology, 87(4), 1913-1920. https://journals.physiology.org/doi/full/10.1152/jn.00885.2001